This company listing is no longer active
2VN Stock Overview
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Biohaven Pharmaceutical Holding Company Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$153.00 |
52 Week High | US$158.00 |
52 Week Low | US$78.50 |
Beta | 1.04 |
1 Month Change | 2.69% |
3 Month Change | 10.07% |
1 Year Change | 24.80% |
3 Year Change | 292.31% |
5 Year Change | 461.49% |
Change since IPO | 654.07% |
Recent News & Updates
Recent updates
Shareholder Returns
2VN | DE Biotechs | DE Market | |
---|---|---|---|
7D | -1.9% | 3.3% | 1.6% |
1Y | 24.8% | 35.8% | 6.4% |
Return vs Industry: 2VN exceeded the German Biotechs industry which returned -10.9% over the past year.
Return vs Market: 2VN exceeded the German Market which returned -26.6% over the past year.
Price Volatility
2VN volatility | |
---|---|
2VN Average Weekly Movement | 1.8% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2VN has not had significant price volatility in the past 3 months.
Volatility Over Time: 2VN's weekly volatility has decreased from 11% to 2% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 928 | Vlad Coric | https://www.biohavenpharma.com |
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases. Its portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have four migraine attacks per month. It is also developing a pipeline of late-stage product candidates across five mechanistic platforms, including CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; MPO inhibition for amyotrophic lateral sclerosis; and Kv7 Ion Channel Activators (Kv7) for focal epilepsy and neuronal hyperexcitability, as well as myostatin inhibition for neuromuscular diseases.
Biohaven Pharmaceutical Holding Company Ltd. Fundamentals Summary
2VN fundamental statistics | |
---|---|
Market cap | €10.99b |
Earnings (TTM) | -€1.04b |
Revenue (TTM) | €873.87m |
12.6x
P/S Ratio-10.6x
P/E RatioIs 2VN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2VN income statement (TTM) | |
---|---|
Revenue | US$859.68m |
Cost of Revenue | US$276.59m |
Gross Profit | US$583.10m |
Other Expenses | US$1.60b |
Earnings | -US$1.02b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -14.29 |
Gross Margin | 67.83% |
Net Profit Margin | -118.82% |
Debt/Equity Ratio | -125.1% |
How did 2VN perform over the long term?
See historical performance and comparison